March 10, 2022– The 14 drug companies that have imposed or announced restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought in more than a half-trillion dollars in revenues in 2021. The banner year for the drugmakers occurred as hospitals reported increasing losses of 340B savings from the cuts. Last month, most drug companies … [Read more...]
Diabetes Care Bears the Brunt of Drugmakers’ 340B Restrictions
Sept. 23, 2021– The eight pharmaceutical companies that are restricting the discounts they offer through the 340B drug pricing program are blocking safety-net hospitals’ access to savings on a wide range of prescription drugs. But perhaps in no area is this more evident than when looking at the prices of diabetes drugs and the levels of lost 340B resources that otherwise would … [Read more...]
The Human Toll of Drug Company Restrictions on 340B
May 26, 2021– Anne Webster knew last fall how bad things would get for many of her patients when the drug company Eli Lilly unilaterally pulled out of offering discounts through the 340B drug pricing program on medications dispensed at community pharmacies. As the nurse practitioner at the endocrinology clinic for UnityPoint Health Methodist in Peoria, Ill., she cares for many … [Read more...]
New Federal 340B Order Is Major Step Toward Restoring Drug Discounts
May 19, 2021– The Health Resources & Services Administration (HRSA) has taken decisive action to put a stop to the actions of six drug companies that are denying 340B drug pricing program discounts for medications dispensed at community pharmacies. The action could lead to the end of a nearly year-long dispute pitting for-profit pharmaceutical companies against nonprofit … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]